ImmunoGen Inc. [NASDAQ: IMGN] gained 2.48% on the last trading session, reaching $4.96 price per share at the time. The company report on March 10, 2022 that ImmunoGen to Present Full Results from SORAYA Trial of Mirvetuximab Soravtansine in Ovarian Cancer at the Society of Gynecologic Oncology Annual Meeting.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free.
Data from Pivotal Trial to be Highlighted in Oral Presentation on Saturday, March 19.
Investor Event to be Held Sunday, March 20 at 7:30 am MST.
ImmunoGen Inc. represents 220.95 million in outstanding shares, while the company has a total market value of $1.09 billion with the latest information. IMGN stock price has been found in the range of $4.68 to $4.97.
If compared to the average trading volume of 2.70M shares, IMGN reached a trading volume of 5242850 in the most recent trading day, which is why market watchdogs consider the stock to be active.
Here is what top equities market gurus are saying about ImmunoGen Inc. [IMGN]:
Based on careful and fact-backed analyses by Wall Street experts, the current consensus on the target price for IMGN shares is $11.50 per share. Analysis on target price and performance of stocks is usually carefully studied by market experts, and the current Wall Street consensus on IMGN stock is a recommendation set at 1.90. This rating represents a strong Buy recommendation, on the scale from 1 to 5, where 5 would mean strong sell, 4 represents Sell, 3 is Hold, and 2 indicates Buy.
BMO Capital Markets have made an estimate for ImmunoGen Inc. shares, keeping their opinion on the stock as Outperform, with their previous recommendation back on February 11, 2022. While these analysts kept the previous recommendation, Jefferies dropped their target price from $7 to $12. The new note on the price target was released on December 01, 2021, representing the official price target for ImmunoGen Inc. stock. Previously, the target price had yet another raise to $11, while H.C. Wainwright analysts kept a Buy rating on IMGN stock.
The Average True Range (ATR) for ImmunoGen Inc. is set at 0.35, with the Price to Sales ratio for IMGN stock in the period of the last 12 months amounting to 15.65. The Price to Book ratio for the last quarter was 3.37, with the Price to Cash per share for the same quarter was set at 2.17.
Trading performance analysis for IMGN stock
ImmunoGen Inc. [IMGN] fell into the red zone at the end of the last week, falling into a negative trend and dropping by -7.81. With this latest performance, IMGN shares dropped by -13.89% in over the last four-week period, additionally sinking by -11.43% over the last 6 months – not to mention a drop of -44.33% in the past year of trading.
Overbought and oversold stocks can be easily traced with the Relative Strength Index (RSI), where an RSI result of over 70 would be overbought, and any rate below 30 would indicate oversold conditions. An RSI rate of 50 would represent a neutral market momentum. The current RSI for IMGN stock in for the last two-week period is set at 41.07, with the RSI for the last a single of trading hit 38.75, and the three-weeks RSI is set at 42.36 for ImmunoGen Inc. [IMGN]. The present Moving Average for the last 50 days of trading for this stock 5.74, while it was recorded at 5.25 for the last single week of trading, and 5.98 for the last 200 days.
ImmunoGen Inc. [IMGN]: A deeper dive into fundamental analysis
Operating Margin for any stock indicates how profitable investing would be, and ImmunoGen Inc. [IMGN] shares currently have an operating margin of -179.04 and a Gross Margin at +97.11. ImmunoGen Inc.’s Net Margin is presently recorded at -199.41.
Return on Equity for this stock declined to -67.11, with Return on Assets sitting at -31.63.
ImmunoGen Inc.’s liquidity data is similarly interesting compelling, with a Quick Ratio of 5.00 and a Current Ratio set at 5.00.
An analysis of insider ownership at ImmunoGen Inc. [IMGN]
There are presently around $918 million, or 86.90% of IMGN stock, in the hands of institutional investors. The top three institutional holders of IMGN stocks are: RA CAPITAL MANAGEMENT, L.P. with ownership of 20,241,458, which is approximately 9.904% of the company’s market cap and around 0.10% of the total institutional ownership; VANGUARD GROUP INC, holding 15,131,752 shares of the stock with an approximate value of $73.24 million in IMGN stocks shares; and BLACKROCK INC., currently with $71.94 million in IMGN stock with ownership of nearly -3.371% of the company’s market capitalization.
135 institutional holders increased their position in ImmunoGen Inc. [NASDAQ:IMGN] by around 33,449,460 shares. Additionally, 83 investors decreased positions by around 20,357,240 shares, while 45 investors held positions by with 135,952,662 shares. The mentioned changes placed institutional holdings at 189,759,362 shares, according to the latest SEC report filing. IMGN stock had 45 new institutional investments in for a total of 15,921,377 shares, while 28 institutional investors sold positions of 5,248,693 shares during the same period.